Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test-retest paradigm in mice.

作者: Nadège Ripoll , Martine Hascoët , Michel Bourin

DOI: 10.1016/J.BBR.2005.07.013

关键词:

摘要: Abstract The four-plates test (FPT) is an animal model of anxiety which allows the detection anxiolytic effect not only benzodiazepines (BZDs) but also other non-BZDs compounds such as antidepressants (ADs). Furthermore, DOI, a 5-HT2A/2C agonist, has been shown to exert anxiolytic-like in this model. Retesting mice models (test–retest paradigm) induces anxiogenic-like and loss effects response BZDs ADs. On contrary, DOI reported oppose fear potentiation induced by trial 1 FPT. Despite considered one most selective 5-HT2A available, it acts agonist at all three 5-HT2 receptor subtypes (5-HT2A, 5-HT2B 5-HT2C). aim study was thus investigate FPT test–retest paradigm, subtype(s) involved DOI-induced experienced mice. (0.25–4 mg/kg) agonists, 5-HT2B, BW 723C86 (1–16 mg/kg) 5-HT2C, RO 60-0175 have studied. Then, antagonism studies were conducted combinating antagonist SR 46349B, 5-HT2B/2C SB 206553 or 5-HT2C RS 10-2221 (at doses 0.1 1 mg/kg) with (1 mg/kg). Our shows that had no on retesting mice, whereas exerted naive By contrast neither nor 46349B antagonized anti-punishment effect. Diazepam included positive control increased each case number punished passages findings altogether suggest exerts its paradigm through receptors.

参考文章(87)
V Audinot, M Brocco, S Veiga, R Schreiber, A Gobert, M J Millan, (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. Journal of Pharmacology and Experimental Therapeutics. ,vol. 273, pp. 101- 112 ,(1995)
C Congy, M Rinaldi-Carmona, B Labeeuw, P Soubrie, G Neliat, G Le Fur, B Gautret, V Santucci, J C Breliere, J Simiand, Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist Journal of Pharmacology and Experimental Therapeutics. ,vol. 262, pp. 759- 768 ,(1992)
Roh-Yu Shen, Rodrigo Andrade, None, 5-Hydroxytryptamine2 receptor facilitates GABAergic neurotransmission in rat hippocampus. Journal of Pharmacology and Experimental Therapeutics. ,vol. 285, pp. 805- 812 ,(1998)
Junji Ichikawa, Hideo Ishii, Stefania Bonaccorso, Wiley L. Fowler, Ian A. O'Laughlin, Herbert Y. Meltzer, 5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release Journal of Neurochemistry. ,vol. 76, pp. 1521- 1531 ,(2001) , 10.1046/J.1471-4159.2001.00154.X
E.A. Pehek, H.G. McFarlane, K. Maguschak, B. Price, C.P. Pluto, M100,907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex Brain Research. ,vol. 888, pp. 51- 59 ,(2001) , 10.1016/S0006-8993(00)03004-3
François Jenck, Jean-Luc Moreau, Hemmie H.G Berendsen, Michael Boes, Chris L.E Broekkamp, James R Martin, Jürgen Wichmann, Anton M.L Van Delft, Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats European Neuropsychopharmacology. ,vol. 8, pp. 161- 168 ,(1998) , 10.1016/S0924-977X(97)00055-2
Analia Bortolozzi, Merce Amargos-Bosch, Albert Adell, Llorenc Diaz-Mataix, Jordi Serrats, Sebastia Pons, Francesc Artigas, In vivo modulation of 5‐hydroxytryptamine release in mouse prefrontal cortex by local 5‐HT2A receptors: effect of antipsychotic drugs European Journal of Neuroscience. ,vol. 18, pp. 1235- 1246 ,(2003) , 10.1046/J.1460-9568.2003.02829.X
Sandra E. File, Peter S. Mabbutt, Paul K. Hitchcott, Characterisation of the phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology. ,vol. 102, pp. 98- 101 ,(1990) , 10.1007/BF02245751